Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Thrombocytopenia 1Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × romiplostim × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT03362177 2026-02-11

RECITE

Amgen

Phase 3 Completed
165 enrolled 22 charts
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01444417 2017-02-09

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Amgen

Phase 3 Completed
62 enrolled 16 charts 1 FDA
Classical hematology

Purpura, Thrombocytopenic, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡